Financial Performance - Operating revenue for the first nine months reached CNY 5,104,737,548.85, a growth of 30.28% year-on-year[6] - Net profit attributable to shareholders surged by 526.52% to CNY 508,027,590.58 for the first nine months[6] - Basic and diluted earnings per share both rose by 285.71% to CNY 0.54[6] - Cash flow from operating activities increased by 54.07% to CNY 423,145,480.07 for the first nine months[6] - The weighted average return on equity improved by 4.96 percentage points to 6.84%[6] - Total operating revenue for Q3 2018 reached ¥1,712,177,235.47, an increase of 19.5% compared to ¥1,433,081,900.84 in Q3 2017[27] - Net profit for Q3 2018 was ¥35,846,086.07, a decrease of 10.4% from ¥40,253,053.10 in Q3 2017[29] - The company reported a total profit of ¥59,151,885.52 for Q3 2018, compared to ¥55,755,129.82 in Q3 2017, indicating a growth of 7.5%[28] - Operating profit for the first nine months of 2018 was ¥677,873,461.59, significantly higher than ¥210,970,819.51 in the previous year[30] - Total comprehensive income for the first nine months of 2018 was ¥560,851,389.85, compared to ¥134,344,592.86 in the previous year[31] Assets and Liabilities - Total assets increased by 2.82% to CNY 10,069,374,385.25 compared to the end of the previous year[6] - Current assets totaled ¥4,794,325,461.70, up from ¥4,513,271,657.19, indicating an increase of about 6.2%[19] - Inventory increased to ¥1,187,842,701.58 from ¥970,651,902.78, representing a growth of approximately 22.4%[19] - Total liabilities decreased to ¥1,860,801,569.78 from ¥2,014,236,875.72, a reduction of about 7.6%[21] - The non-current assets totaled ¥5,275,048,923.55, slightly down from ¥5,280,140,110.87, indicating a decrease of approximately 0.1%[20] - The total equity attributable to shareholders increased to ¥7,730,784,091.64 from ¥7,289,230,174.34, reflecting a growth of about 6.1%[21] - The total liabilities as of Q3 2018 were ¥1,419,794,086.17, down from ¥1,635,124,622.58 in the previous year, representing a decrease of 13.2%[28] - The total equity increased to ¥7,740,253,645.77 in Q3 2018, compared to ¥7,234,660,806.06 in Q3 2017, reflecting an increase of 7.0%[28] Cash Flow - Cash flow from operating activities for the first nine months of 2018 was ¥423,145,480.07, an increase of 54.0% from ¥274,643,765.13 in the same period last year[34] - Operating cash inflow for the first nine months of 2018 reached ¥3,987,774,985.54, a significant increase of 65.4% compared to ¥2,412,317,580.31 in the same period last year[37] - Net cash flow from operating activities for Q3 2018 was ¥498,071,806.44, up from ¥427,262,604.71 in Q3 2017, reflecting a growth of 16.5%[38] - Total cash and cash equivalents at the end of Q3 2018 amounted to ¥950,819,240.64, compared to ¥864,383,729.38 at the end of Q3 2017, indicating an increase of 10%[38] - Cash outflow from investment activities for Q3 2018 was ¥526,408,453.02, down from ¥666,871,124.46 in Q3 2017, showing a reduction of 21%[38] - Cash inflow from financing activities in Q3 2018 totaled ¥380,000,000.00, compared to ¥263,639,900.00 in Q3 2017, representing a growth of 44%[38] - The net cash flow from financing activities for Q3 2018 was -¥24,731,465.05, an improvement from -¥89,719,275.16 in Q3 2017[38] Shareholder Information - The total number of shareholders reached 78,244 by the end of the reporting period[10] - The company repurchased and canceled 350,000 restricted stocks due to the departure of five incentive plan participants, reducing total shares from 96,560.8 million to 96,525.8 million[14] Expenses - The company's sales expenses surged by 221.73% to ¥1,090,458,471.97, primarily due to increased sales of self-produced formulations[12] - Research and development expenses for Q3 2018 amounted to ¥73,765,537.25, an increase of 23.1% from ¥59,918,798.53 in Q3 2017[28] - Sales expenses for Q3 2018 were ¥347,646,968.02, a significant increase from ¥171,261,004.03 in Q3 2017, indicating increased investment in marketing[30] - Cash paid to employees and for employee benefits in Q3 2018 was ¥424,388,875.72, an increase of 27.4% from ¥333,169,202.23 in Q3 2017[38]

Financial Performance - The company's operating revenue for the first half of 2018 reached CNY 3,392,560,313.38, representing a 36.51% increase compared to CNY 2,485,221,092.83 in the same period last year[20]. - Net profit attributable to shareholders was CNY 468,719,046.45, a significant increase of 419.86% from CNY 90,162,965.15 year-on-year[20]. - Basic earnings per share rose to CNY 0.50, up 431.91% from CNY 0.094 in the previous year[22]. - The weighted average return on net assets increased to 6.22%, up by 4.94 percentage points compared to 1.28% in the same period last year[22]. - The net cash flow from operating activities was CNY 195,822,912.81, slightly up by 0.53% from CNY 194,796,558.63 in the previous year[20]. - Total operating revenue for the first half of 2018 reached CNY 3,392,560,313.38, a significant increase from CNY 2,485,221,092.83 in the same period last year, representing a growth of approximately 36.5%[111]. - The total comprehensive income for the period was CNY 486,484,705.35, compared to CNY 98,482,092.18 in the previous year, indicating a growth of 392.5%[115]. - The company reported a total profit of CNY 547,828,591.64, compared to CNY 116,167,754.44 in the previous year, marking an increase of 371.5%[114]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,137,862,530.15, reflecting a 3.52% increase from CNY 9,793,411,768.06 at the end of the previous year[21]. - Net assets attributable to shareholders increased to CNY 7,712,462,487.62, a growth of 5.81% from CNY 7,289,230,174.34 at the end of the previous year[21]. - The company's total liabilities decreased to CNY 1,938,248,461.50 from CNY 2,014,236,875.72, reflecting a reduction of approximately 3.77%[105]. - The total equity increased to CNY 8,199,614,068.65, up from CNY 7,779,174,892.34, representing a growth of about 5.39%[105]. - The company reported a 455.46% increase in current liabilities due within one year, totaling CNY 78,325,750.00[50]. Investments and R&D - The company applied for 14 international and domestic invention patents, with 5 domestic patents granted during the reporting period[40]. - Research and development expenses increased by 20.48% to CNY 124,866,861.25 compared to the previous year[47]. - The company is advancing the clinical research of anti-tumor drug HER2-ADC and has made progress in the registration of generic drugs[39]. - The sterile powder injection project reported a loss of CNY 87.03 million due to pending FDA approval[55]. Market and Industry Position - The company holds a significant position in the production of fat-soluble vitamins and antibiotic products, with quality meeting international advanced standards[36]. - The vitamin industry shows steady low growth in demand, driven by downstream sectors such as feed, food, and pharmaceuticals[31]. - The company’s main business includes life nutrition products, pharmaceutical manufacturing, and pharmaceutical commerce, with no changes reported during the period[27]. Environmental Compliance - The company is committed to strict compliance with environmental regulations to mitigate risks associated with production and safety[63]. - The company has implemented pollution prevention facilities across its subsidiaries, ensuring all systems are operational and compliant with discharge standards[77]. - The company has established an emergency response plan for environmental incidents, which is reported to the local environmental protection bureau[80]. - Environmental self-monitoring plans have been implemented, with monthly testing for total nitrogen, total phosphorus, and BOD5, and online monitoring for ammonia nitrogen, COD, and pH levels[81]. Shareholder Information - The largest shareholder, Changxin Investment Development Co., Ltd., reduced its holdings by 9,120,616 shares, now holding 208,192,361 shares, representing 21.56% of total shares[89]. - Guotou High-tech Investment Co., Ltd. remains stable with 151,127,573 shares, accounting for 15.65% of total shares[89]. - The report indicates that there are no known relationships or concerted actions among shareholders holding more than 5% of the company's shares[90]. - The report highlights that there are no changes in the controlling shareholder or actual controller[92]. Financial Management - The company reported a significant increase in sales expenses by 389.95% due to the rise in self-produced formulation product sales[47]. - Financial expenses rose by 2,973.57% to CNY 26,797,302.86 primarily due to increased exchange losses[48]. - Income tax expenses surged by 258.71% to CNY 84,445,739.74, attributed to the increase in the parent company's total profit[48]. - The company reported a profit distribution of CNY -77,248,640.00 to shareholders, indicating a loss allocation for the period[124]. Accounting Policies - The company has not disclosed any changes in accounting policies or significant accounting errors during the reporting period[85]. - The company adheres to the accounting standards for enterprises, ensuring the financial statements reflect a true and complete picture of its financial status[138]. - The company recognizes financial assets when it becomes a party to the financial instrument contract, measuring them initially at fair value[149]. - The company applies the expected unit credit method for defined benefit plans, discounting obligations to determine their present value and service costs[182].

Financial Performance - Net profit attributable to shareholders surged by 1,838.06% to CNY 465,340,324.88 year-on-year[6] - Operating revenue rose by 61.68% to CNY 1,922,400,190.61 compared to the same period last year[6] - Basic earnings per share increased by 1,533.33% to CNY 0.49[6] - The company's operating revenue for Q1 2018 was RMB 1,922,400,190.61, representing a 61.68% increase compared to RMB 1,189,011,872.41 in the same period last year[11] - Net profit for Q1 2018 was CNY 467,692,127.69, compared to CNY 20,787,655.10 in Q1 2017, marking an increase of about 2,245.5%[28] - Operating profit for Q1 2018 was CNY 533,995,694.06, a substantial rise from CNY 27,580,829.21 in the previous year, indicating a growth of approximately 1,837.5%[28] - Total operating revenue for Q1 2018 reached CNY 1,488,874,043.89, a significant increase from CNY 676,001,190.15 in the same period last year, representing a growth of approximately 120.5%[29] - The total comprehensive income for Q1 2018 was CNY 486,404,648.96, compared to CNY 28,776,702.26 in Q1 2017, reflecting a growth of about 1,592.5%[28] Assets and Liabilities - Total assets increased by 5.16% to CNY 10,298,316,252.96 compared to the end of the previous year[6] - Total liabilities stood at ¥1,558,254,524.78, down from ¥1,635,124,622.58, marking a decrease of approximately 4.7%[23] - Current liabilities decreased to ¥1,345,655,704.79 from ¥1,455,381,458.02, indicating a reduction of about 7.5%[23] - Owner's equity increased to ¥7,682,572,900.26 from ¥7,234,660,806.06, representing a growth of about 6.2%[23] - Non-current assets totaled ¥5,303,238,335.47, showing a slight increase from ¥5,256,120,262.79 at the beginning of the year[22] Cash Flow - Net cash flow from operating activities decreased by 860.76% to -CNY 149,119,375.92[6] - Cash received from the sale of goods and services increased to 1,753,993,052.52, up from 1,232,859,878.53, reflecting a growth of approximately 42.3%[33] - Total cash inflow from operating activities amounted to 1,846,391,146.85, compared to 1,321,954,340.49 in the prior period, marking an increase of about 39.6%[33] - Cash outflow from operating activities rose to 1,995,510,522.77, up from 1,302,352,959.02, representing an increase of approximately 53.3%[33] - The net cash flow from investment activities was 155,071,288.04, a significant improvement from -206,253,654.61 in the previous period[34] - Cash inflow from investment activities totaled 291,887,589.22, compared to 6,225,136.47 in the prior period, indicating a substantial increase[34] - The net cash flow from financing activities was 77,657,311.98, compared to -49,019,392.30 in the previous period, indicating a positive shift in financing[34] Shareholder Information - The total number of shareholders reached 48,172 at the end of the reporting period[10] - The top shareholder, New Changxing Changxin Investment Development Co., Ltd., holds 22.43% of shares[10] Government Subsidies and Non-Recurring Items - The company received government subsidies amounting to CNY 6,631,692.79 during the reporting period[8] - Non-recurring losses totaled CNY -7,838,663.08, impacting overall profitability[8] Inventory and Expenses - Inventory increased by 30.84% to RMB 1,269,993,500.48 from RMB 970,651,902.78, attributed to the rise in stock of finished goods[11] - Financial expenses surged by 2,691.26% to RMB 42,773,878.26, primarily due to increased exchange losses[11] - The company incurred sales expenses of CNY 382,826,040.94 in Q1 2018, compared to CNY 53,988,917.22 in Q1 2017, representing a dramatic increase of approximately 608.5%[28] - Total operating costs for Q1 2018 amounted to CNY 1,395,457,532.02, up from CNY 1,161,703,140.84 in the same quarter last year, which is an increase of about 20.2%[28] Taxation - The company reported a 489.07% increase in income tax expenses to RMB 66,553,580.53, driven by a rise in total profit[11]

Financial Performance - In 2017, Zhejiang Medicine achieved a revenue of CNY 5,692,580,365.44, representing a year-on-year increase of 7.83% compared to CNY 5,279,204,031.07 in 2016[21] - The net profit attributable to shareholders of the parent company for 2017 was CNY 253,145,602.27, a decrease of 43.76% from CNY 450,102,013.98 in 2016[21] - The net profit after deducting non-recurring gains and losses was CNY 213,434,574.32, down 53.29% from CNY 456,941,736.82 in the previous year[21] - Basic earnings per share decreased by 43.75% to CNY 0.27 in 2017 from CNY 0.48 in 2016[22] - The weighted average return on equity fell by 3.07 percentage points to 3.57% in 2017 compared to 6.64% in 2016[22] - Total revenue for Q4 2017 reached CNY 1,774,277,371.77, marking an increase from CNY 1,433,081,900.84 in Q3 2017[23] - Net profit attributable to shareholders for Q4 2017 was CNY 121,690,457.78, up from CNY 41,292,179.34 in Q3 2017[23] - The company reported a total revenue of approximately 602.56 million CNY for the period, with a gross profit of around 465.14 million CNY, indicating a gross margin of approximately 77.1%[86] - The company reported a significant increase in annual revenue, reaching 1.2 billion RMB, representing a 15% year-over-year growth[178] Cash Flow and Assets - Operating cash flow net amount for 2017 was CNY 503,468,945.03, an increase of 49.78% compared to CNY 336,135,774.91 in 2016[21] - Total assets at the end of 2017 reached CNY 9,793,411,768.06, reflecting an 11.11% increase from CNY 8,814,303,895.58 at the end of 2016[21] - The net assets attributable to shareholders of the parent company increased by 4.46% to CNY 7,289,230,174.34 from CNY 6,978,220,941.10 in 2016[21] - The company's net cash flow from operating activities was CNY 503.47 million, up 49.78% year-on-year[47] - Investment activities resulted in a net cash outflow of 831.53 million yuan, a 108.59% decrease compared to the previous year's outflow of 398.65 million yuan[62] - Financing activities generated a net cash inflow of 441.35 million yuan, a 131.62% increase from 190.55 million yuan in the previous year[62] Research and Development - Research and development expenses amounted to CNY 257.55 million, reflecting an 18.26% increase from the previous year[47] - The company applied for 563 international and domestic invention patents, with 259 patents granted by the end of the reporting period[42] - The company is focusing on the development of anti-infection drugs, vitamin drugs, diabetes medications, and anti-tumor drugs in the future[87] - The company has established two technical platforms in the vitamin product field, focusing on green chemistry and microencapsulation of active ingredients[87] - The company is committed to research and development, focusing on improving the efficacy and safety of its nutritional products[74] Product and Market Development - The company’s main business includes life nutrition products and pharmaceutical manufacturing, with a focus on vitamins and antibiotic raw materials[30] - The company launched three new health products, including lutein chewable tablets, which have quickly gained market leadership in eye care[69] - The company’s innovative drug, Apixaban, received the first drug marketing license in China, with its sodium chloride injection included in priority review products[71] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[178] - New product launches contributed to 30% of total sales, indicating strong market reception[177] Sales and Revenue Breakdown - Sales revenue from life nutrition products reached CNY 2.44 billion, accounting for 42.87% of total revenue, with a year-on-year increase of 4.82%[45] - The pharmaceutical manufacturing segment generated CNY 1.35 billion in sales, representing a 33.25% increase year-on-year[45] - The pharmaceutical commercial segment reported sales of CNY 1.87 billion, a decrease of 2.60% compared to the previous year[45] - The revenue from the anti-infection category was CNY 978.43 million, with a gross profit margin of 71.21%, which increased by 39.55% year-on-year[96] Risk Management and Compliance - The company has not identified any significant risks that could materially affect its operations during the reporting period[8] - The company is addressing potential risks from drug price reductions due to policy changes and is monitoring exchange rate fluctuations to mitigate financial impacts[118] - The company has committed to maintaining the accuracy and completeness of its financial reports, as confirmed by the auditing firm Tianjian[4] Corporate Governance and Shareholder Information - The company has committed to avoiding competition with its controlling shareholders and has adhered to this commitment throughout the reporting period[126] - The company has a transparent information disclosure process, ensuring timely and accurate communication with shareholders[195] - The board of directors consists of 11 members, including 4 independent directors, and held 7 meetings during the reporting period[194] - The company has established a performance evaluation mechanism for senior management, linking their annual compensation to the achievement of business goals[200] Environmental and Social Responsibility - The company invested over 400 million yuan in environmental protection measures, minimizing environmental impact during production[72] - The company has been actively involved in charitable donations, including new scholarships to support education at several universities[143] - The company’s environmental center successfully converted waste into steam for production, demonstrating economic benefits that cover operational costs[145]

浙江医药股份有限公司 2017 年第三季度报告 公司代码：600216 公司简称：浙江医药 浙江医药股份有限公司 2017 年第三季度报告 1 / 20 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 浙江医药股份有限公司 2017 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | | 上年度末 | | | 本报告期末比上年度 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 末增减(%) | | | 总资产 | 9,464,742,337.77 | | 8,814,303,895.58 | | | | 7.38 | | 归属于上市公司股东 | 6,977,793,545.19 | | 6,978,220,941.10 | | | | -0.01 | | 的净资产 | | | | | | | | | | 年初至报告期末 ...

浙江医药股份有限公司 2017 年半年度报告 公司代码：600216 公司简称：浙江医药 浙江医药股份有限公司 2017 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 李男行 | 工作原因 | 李春波 | | 独立董事 | 彭师奇 | 工作原因 | 吴弘 | | 独立董事 | 朱建伟 | 工作原因 | 黄董良 | 三、 本半年度报告未经审计。 四、 公司负责人李春波、主管会计工作负责人王明达及会计机构负责人（会计主管人员）冯丹音 声明：保证半年度报告中财务报告的真实、准确、完整。 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性陈述不构成公司对投资者的实质承诺，敬请投 资者注意投资风险。 七、 是否存 ...

浙江医药股份有限公司 2017 年第一季度报告 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 浙江医药股份有限公司 2017 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末 增减(%) 总资产 8,653,704,119.74 8,814,303,895.58 -1.82 归属于上市公司股东的 净资产 7,026,797,327.72 6,978,220,941.10 0.70 年初至报告期末 上年初至上年报告期末 比上年同期增减(%) 经营活动产生的现金流 量净额 19,601,381.47 -179,730,608.98 110.91 年初至报告期末 上年初至上年报告期末 比上年同期增减（%） 营业收入 1,189,011,872.41 1,308,922,245.86 -9.16 归属于上市公司股东的 净利润 24,010,668.25 64,722,190.63 -62.9 ...

浙江医药股份有限公司 2016 年年度报告 公司代码：600216 公司简称：浙江医药 浙江医药股份有限公司 2016 年年度报告 重要提示 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 经天健会计师事务所(特殊普通合伙)审计，2016 年度归属于母公司股东的净利润为 450,102,013.98 元，母公司净利润为 609,583,961.17 元。按《公司章程》规定，以 2016 年 度实现的母公司净利润 609,583,961.17 元为基数，提取 10%法定盈余公积金 60,958,396.12 元，提取 5%的任意盈余公积金 30,479,198.06 元后，加上母公司期初未分配利润 3,399,381,022.04 元，期末母公司可供股东分配利润为 3,870,721,989.03 元。公司拟以 2016 年 12 月 31 日公司总股本 96,284.80 万股为基数，向全体股东每 10 股派送现金红利 1.45 元 （含税），计派送现金红利 139,612,960.00 元，剩余未分配利润结转下一年度。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战 ...

| 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 12 | 浙江医药股份有限公司 2016 年第三季度报告 一、 重要提示 浙江医药股份有限公司 2016 年第三季度报告 公司代码：600216 公司简称：浙江医药 浙江医药股份有限公司 2016 年第三季度报告 1 / 26 $$\mathbb{H}\,{\overline{{\exists k}}}$$ 二、 公司主要财务数据和股东变化 2.1 主要财务数据 1.4 本公司第三季度报告未经审计。 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人李春波、主管会计工作负责人王明达及会计机构负责人（会计主管人员）冯丹音 保证季度报告中财务报表的真实、准确、完整。 浙江医药股份有限公司 2016 年第三季度报告 | 基 本 每 股 收 益 | 0.43 ...

浙江医药股份有限公司 2016 年半年度报告 公司代码：600216 公司简称：浙江医药 浙江医药股份有限公司 2016 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 夏兵 | 工作原因 | 李俊喜 | | 董事 | 李男行 | 工作原因 | 李春波 | 五、 经董事会审议的报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 其他 三、 本半年度报告未经审计。 四、 公司负责人李春波、主管会计工作负责人王明达及会计机构负责人（会计主管人员）冯丹音 声明：保证半年度 ...